Cocrystal pharma receives australian regulatory clearance to initiate phase 1 study of cc-42344 for the treatment of pandemic and seasonal influenza

Bothell, wash., oct. 06, 2021 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza, hepatitis c viruses and noroviruses, announces receipt of clearance from an australian human research ethics committee (hrec) to initiate a phase 1 trial with its orally administered pb2 inhibitor cc-42344 for the treatment of pandemic and seasonal influenza a.
COCP Ratings Summary
COCP Quant Ranking